OnabotulinumtoxinA: Preventive treatment for chronic migraine

Current Pain and Headache Reports

Volumn 15, Issue 1, 2011, Pages 4-7

  Chen, Shih Pin ^a,b   Fuh, Jong Ling ^a,b   Wang, Shuu Jiun ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; ONABOTULINUMTOXIN A; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; NECK PAIN; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79551532031     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-010-0150-6     Document Type: Article

References (17)

1. J Munakata E Hazard D Serrano, et al. 2009 Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study Headache 49 498 508 19245386
2. Headache Classification Subcommittee of the International Headache Society 2004 The International Classification of Headache Disorders: 2nd edition Cephalalgia 24 Suppl 1 9 160
3. DW Dodick 2006 Clinical practice. Chronic daily headache N Engl J Med 354 158 165 1:CAS:528:DC%2BD28XisFWmtA%3D%3D 16407511 (Published erratum appears in N Engl J Med 2006, 354:884.)
4. KR Aoki 2002 Physiology and pharmacology of therapeutic botulinum neurotoxins Curr Probl Dermatol 30 107 116 1:CAS:528:DC%2BD38XltlOlt7g%3D 12471704
5. WJ Binder MF Brin A Blitzer LD Schoenrock JM Pogoda 2000 Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study Otolaryngol Head Neck Surg 123 669 676 1:STN:280:DC%2BD3M%2FntF2rtg%3D%3D 11112955
6. WJ Schulte-Mattler E Leinisch 2008 Evidence based medicine on the use of botulinum toxin for headache disorders J Neural Transm 115 647 651 1:STN:280:DC%2BD1c3ktFGiuw%3D%3D 17994180
7. DW Dodick A Mauskop AH Elkind, et al. 2005 Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study Headache 45 315 324 15836567
8. S Silberstein P Tfelt-Hansen DW Dodick, et al. 2008 Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults Cephalalgia 28 484 495 1:STN:280:DC%2BD1c3jvFemtA%3D%3D 18294250 (Published erratum appears in Cephalalgia 2008, 28:679.)
9. AM Blumenfeld JD Schim TJ Chippendale 2008 Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine Headache 48 210 220 18047502
10. NT Mathew SF Jaffri 2009 A double-blind comparison of onabotulinumtoxina (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study Headache 49 1466 1478 19912346
11. E Magalhães C Menezes M Cardeal A Melo 2010 Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine Clin Neurol Neurosurg 112 463 466 20399553
12. HC Diener CF Schorn U Bingel DW Dodick 2008 The importance of placebo in headache research Cephalalgia 28 1003 1011 18727647
13. SD Silberstein RB Lipton DW Dodick, et al. 2007 Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial Headache 47 170 180 17300356
14. HC Diener G Bussone JC Van Oene, et al. 2007 Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study Cephalalgia 27 814 823 17441971 (Published erratum appears in Cephalalgia 2007, 27:962.)
15. KR Aoki 2003 Evidence for antinociceptive activity of botulinum toxin type A in pain management Headache 43 Suppl 1 S9 S15 12887389
16. P Gazerani NS Pedersen C Staahl, et al. 2009 Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin Pain 141 60 69 1:CAS:528:DC%2BD1MXjvFSqtA%3D%3D 19004549
17. Gazerani P, Au S, Dong X, et al.: Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 2010 Aug 20 (Epub ahead of print).